HRP20161236T1 - Kompozicija kaspofugina - Google Patents
Kompozicija kaspofugina Download PDFInfo
- Publication number
- HRP20161236T1 HRP20161236T1 HRP20161236TT HRP20161236T HRP20161236T1 HR P20161236 T1 HRP20161236 T1 HR P20161236T1 HR P20161236T T HRP20161236T T HR P20161236TT HR P20161236 T HRP20161236 T HR P20161236T HR P20161236 T1 HRP20161236 T1 HR P20161236T1
- Authority
- HR
- Croatia
- Prior art keywords
- caspofungin
- pharmaceutically acceptable
- mixture according
- formulation
- excipients
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 24
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 title claims 12
- 229960003034 caspofungin Drugs 0.000 title claims 12
- 108010020326 Caspofungin Proteins 0.000 title claims 11
- 238000009472 formulation Methods 0.000 claims 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 239000006172 buffering agent Substances 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 238000007911 parenteral administration Methods 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- 150000003890 succinate salts Chemical group 0.000 claims 4
- 159000000021 acetate salts Chemical class 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 241000228212 Aspergillus Species 0.000 claims 1
- 241000228197 Aspergillus flavus Species 0.000 claims 1
- 241001225321 Aspergillus fumigatus Species 0.000 claims 1
- 241000228245 Aspergillus niger Species 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 241000222178 Candida tropicalis Species 0.000 claims 1
- 240000002355 Celtis tournefortii var. glabrata Species 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003385 bacteriostatic effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000008223 sterile water Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (20)
1. Smjesa obuhvaća:
a) farmaceutski djelotvornu količinu acetatne soli kaspofungina;
b) farmaceutski prihvatljivu količinu jedne ili više farmaceutski prihvatljive pomoćne tvari djelotvorne za tvorbu liofilizirane torte; i
c) farmaceutski djelotvornu količinu puferskog sredstva, gdje je pufersko sredstvo sukcinat.
2. Smjesa prema zahtjevu 1, naznačena time sto je farmaceutski prihvatljiva sol kaspofungina diacetatna sol kaspofungina.
3. Smjesa prema bilo kojem od prethodnih zahtjeva, naznačeno time da se jedna ili više pomoćnih tvari odabire iz grupe koja se sastoji od razrjeđivača, antioksidansa i konzervansa.
4. Smjesa prema bilo kojem zahtjevu od 1 do 3, naznačeno time da se pomoćne tvari odabiru iz grupe koja se sastoji od sukroze i manitola; ili od njihove kombinacije.
5. Smjesa prema bilo kojem od prethodnih zahtjeva, naznačeno time da ista obuhvaća:
a) farmaceutski djelotvornu količinu acetatne soli kaspofungina;
b) oko 10-200 mg/ml jedne ili više farmaceutski prihvatljive pomoćne tvari djelotvorne za tvorbu
liofilizirane kolača;
c) farmaceutski djelotvorna količina sukcinata djelotvorna za osiguranje farmaceutski prihvatljive
pH vrijednosti.
6. Smjesa prema zahtjevu 5, naznačeno time da ista obuhvaća količinu kaspofungina od oko 42 mg/ml.
7. Smjesa prema zahtjevu 6, naznačeno time da ista obuhvaća:
a) oko 46 mg/ml diacetatne soli kaspofungina;
b) oko 30 mg/ml sukroze i oko 20 mg/ml manitola; i
c) oko 1,5 mg/ml sukcinata.
8. Postupak pripreme smjese kaspofungina prema bilo kojem zahtjevu od 1 do 7
obuhvaćajući slijedeće korake:
a) miješanje vodene otopine koja obuhvaća farmaceutski prihvatljivu količinu jedne ili više pomoćnih tvari s farmaceutski djelotvornom količinom puferskog sredstva; gdje je pufersko sredstvo sukcinat;
b) po želji, prilagođavanje pH vrijednosti povećavanjem bazičnosti u svrhu dobivanja farmaceutski prihvatljive pH vrijednosti;
c) dodavanje farmaceutski prihvatljive količine acetatne soli kaspofungina smjesi pod a)
d) po želji, prilagođavanje pH vrijednosti povećavanjem bazičnosti u svrhu dobivanja farmaceutski
prihvatljive pH vrijednosti;
e) filtriranje otopine dobivene pod d).
9. Postupak pripreme smjese kaspofungina prema zahtjevu 8, naznačeno time da se korak a) provodi prvo pripremom vodene otopine koja obuhvaća farmaceutski djelotvornu količinu puferskog sredstva, pri čemu je pufersko sredstvo sukcinat; a zatim dodavanjem farmaceutski prihvatljive količine jedne ili više pomoćnih tvari otopljenih u vodi navedenoj otopini puferskog sredstva.
10. Postupak pripreme smjese kaspofungina prema zahtjevu 8, pri čemu se korak a) provodi prvo otapanjem farmaceutski prihvatljive količine jedne ili više pomoćnih tvari u vodi; a zatim dodavanjem farmaceutski djelotvorne količine puferskog sredstva; pri čemu je navedeno pufersko sredstvo sukcinat.
11. Postupak prema bilo kojem zahtjevu od 8 do 10, pri čemu se pH vrijednost u koraku b) podešava na vrijednosti od 5,0 do 5,7.
12. Postupak prema bilo kojem zahtjevu od 8 do 10, pri čemu se pH vrijednost u koraku d) podešava na oko 6.
13. Postupak prema bilo kojem zahtjevu od 8 do 12, pri čemu se kaspofungin diacetat dodaje u koraku c).
14. Lipofilizirana formulacija koja se sastoji od smjese koja prije lipofilizacije odgovara smjesi prema bilo kojem zahtjevu od 1 do 7.
15. Formulacija za parenteralnu primjenu koja se sastoji od lipofilizirane formulacije prema zahtjevu 14, pri čemu se navedena lipofilizirana formulacija otapa u farmaceutski prihvatljivoj rekonstituiranoj otopini prikladnoj za parenteralnu primjenu u potrebitih pacijenata.
16. Formulacija za parenteralnu primjenu prema zahtjevu 15 pri čemu se farmaceutski prihvatljiva rekonstituirana otopina odabire iz grupe koja se sastoji od destilirane ili sterilne vode obično korištene za injekcije, fiziološke otopine ili bakteriostatsku vodu.
17. Pribor koji obuhvaća ravnu posudu s lipofiliziranom formulacijom prema zahtjevu 14 i drugu posudu s parenteralno prihvatljivim otapalom za rekonstituciju te, po želji, posudu sa sredstvom za primjenu rekonstituirane otopine u potrebitih pacijenata.
18. Upotreba smjese prema bilo kojem zahtjevu od 1 do 7 u pripremi formulacije za parenteralnu primjenu za liječenje ili sprječavanje gljivične infekcije.
19. Upotreba smjese prema zahtjevu 18, pri čemu je infekcija izazvana gljivicom iz roda Candida ili Aspergillus.
20. Upotreba smjese prema zahtjevu 18, pri čemu je infekcija izazvana gljivicom iz roda C. albicans, C. tropicalis, C. krusel, C. glabrata, A. fumigatus. A. flavus i A. niger.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38433310P | 2010-09-20 | 2010-09-20 | |
| EP11761049.3A EP2618814B1 (en) | 2010-09-20 | 2011-09-19 | Caspofungin composition |
| PCT/EP2011/066202 WO2012038371A1 (en) | 2010-09-20 | 2011-09-19 | Caspofungin composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161236T1 true HRP20161236T1 (hr) | 2016-11-18 |
Family
ID=44677877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161236TT HRP20161236T1 (hr) | 2010-09-20 | 2016-09-28 | Kompozicija kaspofugina |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20120101030A1 (hr) |
| EP (1) | EP2618814B1 (hr) |
| JP (1) | JP5914486B2 (hr) |
| KR (1) | KR20130136466A (hr) |
| CN (1) | CN103118663A (hr) |
| AU (1) | AU2011304408B2 (hr) |
| CA (1) | CA2810112A1 (hr) |
| DK (1) | DK2618814T3 (hr) |
| ES (1) | ES2593727T3 (hr) |
| HR (1) | HRP20161236T1 (hr) |
| HU (1) | HUE030464T2 (hr) |
| IL (1) | IL225339A0 (hr) |
| MX (1) | MX2013003045A (hr) |
| PL (1) | PL2618814T3 (hr) |
| PT (1) | PT2618814T (hr) |
| RS (1) | RS55216B1 (hr) |
| RU (1) | RU2013114993A (hr) |
| UA (1) | UA111599C2 (hr) |
| WO (1) | WO2012038371A1 (hr) |
| ZA (1) | ZA201302113B (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103212059A (zh) * | 2012-01-18 | 2013-07-24 | 江苏恒瑞医药股份有限公司 | 含有抗真菌药物和乳酸盐缓冲液的组合物 |
| CN103212058A (zh) * | 2012-01-18 | 2013-07-24 | 江苏恒瑞医药股份有限公司 | 含有抗真菌药物和乳酸盐缓冲剂的组合物 |
| WO2014081443A1 (en) * | 2012-11-20 | 2014-05-30 | Fresenius Kabi Usa, Llc | Caspofungin acetate formulations |
| CN103142997A (zh) * | 2013-03-13 | 2013-06-12 | 浙江海正药业股份有限公司 | 含有抗真菌剂和琥珀酸盐缓冲液的药物组合物 |
| KR20140123782A (ko) * | 2013-04-15 | 2014-10-23 | 에스케이케미칼주식회사 | 카스포펀진 및 완충제를 포함하는 안정성이 개선된 약학적 조성물 |
| CN104116716A (zh) * | 2013-04-25 | 2014-10-29 | 四川海思科制药有限公司 | 一种含卡泊芬净的冻干粉针剂药物组合物 |
| ES2853349T3 (es) * | 2013-10-07 | 2021-09-15 | Galenicum Health S L U | Formulaciones farmacéuticas estables |
| GR1008818B (el) * | 2015-05-22 | 2016-08-01 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου |
| CN108760937B (zh) * | 2018-07-27 | 2020-12-29 | 杭州华东医药集团新药研究院有限公司 | 醋酸卡泊芬净中残留乙二胺的测定及其应用 |
| CN109758426B (zh) * | 2019-01-24 | 2021-04-27 | 四川制药制剂有限公司 | 一种注射用醋酸卡泊芬净药物组合物及其制备方法 |
| CN110859950B (zh) * | 2019-11-25 | 2021-08-10 | 武汉大学 | 一种用于白念珠菌棘白菌素类药物耐药菌的药物组合物及其应用 |
| EP4364566A1 (en) * | 2022-11-04 | 2024-05-08 | B. Braun Melsungen AG | Anti-fungal composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7673991A (en) * | 1990-03-30 | 1991-10-30 | Smithkline Beecham Corporation | Method for treating fungal infection |
| JP2930823B2 (ja) | 1991-12-11 | 1999-08-09 | 株式会社東芝 | Ｘ線ｃｔスキャナ用検出器及びｘ線検出装置用シンチレータチャネルセパレータ |
| US5378804A (en) | 1993-03-16 | 1995-01-03 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
| US5952300A (en) | 1996-04-19 | 1999-09-14 | Merck & Co., Inc. | Antifungal compositions |
| US20080046580A1 (en) | 2006-06-29 | 2008-02-21 | Nokia Corporation | Account creation system and call processing system |
| CN101516387B (zh) * | 2006-07-26 | 2014-06-04 | 桑多斯股份公司 | 卡泊芬净制剂 |
| BRPI0715113A2 (pt) * | 2006-07-26 | 2013-06-04 | Sandoz Ag Sandoz Sa Sandoz Ltd | formulaÇço de caspofungina |
| JP5537425B2 (ja) | 2007-06-26 | 2014-07-02 | メルク・シャープ・アンド・ドーム・コーポレーション | 凍結乾燥抗真菌組成物 |
| EP2285236A1 (en) * | 2008-05-30 | 2011-02-23 | DSM IP Assets B.V. | Use of succinic acid |
| WO2009158034A1 (en) | 2008-06-25 | 2009-12-30 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Caspofungin free of caspofungin impurity a |
-
2011
- 2011-09-19 WO PCT/EP2011/066202 patent/WO2012038371A1/en active Application Filing
- 2011-09-19 MX MX2013003045A patent/MX2013003045A/es active IP Right Grant
- 2011-09-19 CA CA2810112A patent/CA2810112A1/en not_active Abandoned
- 2011-09-19 DK DK11761049.3T patent/DK2618814T3/en active
- 2011-09-19 PT PT117610493T patent/PT2618814T/pt unknown
- 2011-09-19 PL PL11761049T patent/PL2618814T3/pl unknown
- 2011-09-19 HU HUE11761049A patent/HUE030464T2/en unknown
- 2011-09-19 JP JP2013528699A patent/JP5914486B2/ja not_active Expired - Fee Related
- 2011-09-19 KR KR1020137010070A patent/KR20130136466A/ko not_active Application Discontinuation
- 2011-09-19 CN CN2011800451119A patent/CN103118663A/zh active Pending
- 2011-09-19 RS RS20160810A patent/RS55216B1/sr unknown
- 2011-09-19 UA UAA201304481A patent/UA111599C2/uk unknown
- 2011-09-19 AU AU2011304408A patent/AU2011304408B2/en not_active Ceased
- 2011-09-19 RU RU2013114993/15A patent/RU2013114993A/ru not_active Application Discontinuation
- 2011-09-19 ES ES11761049.3T patent/ES2593727T3/es active Active
- 2011-09-19 EP EP11761049.3A patent/EP2618814B1/en active Active
- 2011-09-20 US US13/237,193 patent/US20120101030A1/en not_active Abandoned
-
2013
- 2013-03-19 IL IL225339A patent/IL225339A0/en unknown
- 2013-03-20 ZA ZA2013/02113A patent/ZA201302113B/en unknown
-
2014
- 2014-11-19 US US14/547,742 patent/US9393307B2/en active Active
-
2016
- 2016-09-28 HR HRP20161236TT patent/HRP20161236T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS55216B1 (sr) | 2017-02-28 |
| IL225339A0 (en) | 2013-06-27 |
| AU2011304408B2 (en) | 2015-01-15 |
| CA2810112A1 (en) | 2012-03-29 |
| JP2013537212A (ja) | 2013-09-30 |
| PT2618814T (pt) | 2016-10-06 |
| ZA201302113B (en) | 2014-05-28 |
| HUE030464T2 (en) | 2017-05-29 |
| CN103118663A (zh) | 2013-05-22 |
| AU2011304408A1 (en) | 2013-03-28 |
| RU2013114993A (ru) | 2014-10-27 |
| PL2618814T3 (pl) | 2017-01-31 |
| EP2618814B1 (en) | 2016-07-27 |
| EP2618814A1 (en) | 2013-07-31 |
| DK2618814T3 (en) | 2016-10-10 |
| ES2593727T3 (es) | 2016-12-12 |
| UA111599C2 (uk) | 2016-05-25 |
| MX2013003045A (es) | 2013-06-24 |
| WO2012038371A1 (en) | 2012-03-29 |
| US20120101030A1 (en) | 2012-04-26 |
| KR20130136466A (ko) | 2013-12-12 |
| US9393307B2 (en) | 2016-07-19 |
| JP5914486B2 (ja) | 2016-05-11 |
| US20150072923A1 (en) | 2015-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161236T1 (hr) | Kompozicija kaspofugina | |
| JP2013537212A5 (hr) | ||
| JP5723030B2 (ja) | エキノカンジン系抗真菌剤であるミカファンギンを含む薬用組成物およびその製造方法と用途 | |
| US20170367969A1 (en) | Palonosetron oral transmucosal film or patch | |
| JP5723031B2 (ja) | エキノカンジン系抗真菌剤であるミカファンギンを含む液体薬用組成物 | |
| Song et al. | Preparation and in vitro–in vivo evaluation of novel ocular nanomicelle formulation of thymol based on glycyrrhizin | |
| CN103784426B (zh) | 阿立哌唑口溶膜剂及其制备方法 | |
| US20110207764A1 (en) | Cyclopolysaccharide compositions | |
| KR101996713B1 (ko) | 진세노사이드 및 인지질 기반 지질나노입자 및 이의 제조방법 | |
| KR101889878B1 (ko) | 적하 가능한 안과용 비마토프로스트 겔 | |
| WO2017073798A1 (ja) | 鼻粘膜投与用医薬組成物 | |
| WO2014102731A1 (en) | Novel pharmaceutical compositions of romidepsin | |
| CN104043103B (zh) | 一种多黏菌素e甲磺酸钠冻干制剂及其制备方法 | |
| CN101474164A (zh) | 一种口服复方紫杉醇胶囊剂及制备方法 | |
| CN103908659A (zh) | Lhrh类似物和齐考诺肽组合物缓释微球制剂及其制备方法 | |
| WO2012029076A3 (en) | Stable pharmaceutical composition | |
| CN103211755A (zh) | 无菌稳定的阿奇霉素滴眼液的生产方法 | |
| CN102614493B (zh) | 一种含有棘白菌素类抗真菌剂卡泊芬净的液体药用组合物 | |
| CN106176626B (zh) | L-丙氨酸-(14-冬凌草甲素)酯胃肠外用药物组合物 | |
| WO2008089709A3 (en) | Oxaliplatin pharmaceutical composition with alcoholic sugar-based buffer | |
| CN102988280B (zh) | 一种加雷沙星滴眼剂 | |
| CN103462906B (zh) | 一种注射用多西他赛纳米粒及其制备方法 | |
| CN101019857A (zh) | 含藤黄酸的可注射胶束制剂及其制备方法 | |
| CN104398501A (zh) | 用于治疗易复发性癌症的聚合物胶束组合物及其制备方法 | |
| CN104739807A (zh) | 一种总蟾毒内酯纳米胶束制剂及其制备方法 |